1-4 of 4
Elisabeth Silkenstedt
Close
Sort by
Journal Articles

Treatment of Relapsed/Refractory MCL

Clinical Trials & Observations
Elisabeth Silkenstedt, Martin Dreyling
Journal: Blood
Blood blood.2023022353.
https://doi.org/10.1182/blood.2023022353
Published: 2024
Journal Articles

Interaction of Mantle Cell Lymphoma with the Microenvironment Induces Phospho Akt-Mediated Resistance Against BTK Inhibition and Can be Overcome By Co-Treatment with a Specific Akt Inhibitor (MK-2206)

Elisabeth Silkenstedt, MD, Claudia Schwandner, Johanna Deuss, Natalie Mack, Yvonne Zimmermann, Martin Dreyling, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2802.
https://doi.org/10.1182/blood-2019-128782
Published: 2019
Journal Articles

PARP14 Is a Novel Therapeutic Target in STAT6 mutant Follicular Lymphoma

Verena Passerini, PhD, Michael Boesl, Elisabeth Silkenstedt, MD, Elisa Osterode, Michael Heide, Robert Kridel, PhD MD, Christoph Ziegenhain, Annette M. Staiger, PhD, German Ott, MD, Monika Szczepanowski, PhD, Julia Richter, PhD, Wolfram Klapper, MD, Andreas Rosenwald, Wolfgang Enard, PhD, Wolfgang Hiddemann, Deepak Bararia, PhD, Zimber-Strobl Ursula, Dr., Oliver Weigert, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2842.
https://doi.org/10.1182/blood-2018-99-118063
Published: 2018
Journal Articles

Cyclin D1 Driven CDK4 Activity Is Responsible for Hypersensitivity to NOXA Inducing Combination Treatment in Mantle Cell Lymphoma (MCL) Cells

Simon Heine, MSc, Elisabeth Silkenstedt, MD, Michael A Dengler, PhD, Kleih Markus, MSc, German Ott, MD, Neus Giménez Carabaza, B.Pharm, Colomer Dolors, PhD, Heiko van der Kuip, PhD, Walter E. Aulitzky, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2811.
https://doi.org/10.1182/blood.V130.Suppl_1.2811.2811
Published: 2017